Specialized Medical (4019) Fundamentals 2026 — P/E 14.3x, Revenue Analysis | SniperIQ
Specialized Medical (4019) is a SA-listed Healthcare company in Medical - Care Facilities with a market capitalization of SAR 3.9B, trading at SAR 15.57 on the SAU. This SniperIQ fundamentals page covers Specialized Medical's valuation (P/E 14.3x, P/B 3.8x), profitability (net margin 17.4%), revenue (SAR 1.5B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Specialized Medical's market cap?
Specialized Medical (4019) has a market capitalization of approximately SAR 3.9B, trading at SAR 15.57 on the SAU. Market cap moves with the live share price.
What is Specialized Medical's P/E ratio?
Specialized Medical's trailing twelve-month P/E ratio is 14.3x, with a price-to-book (P/B) of 3.8x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Specialized Medical?
Specialized Medical runs a net profit margin of 17.4%, a gross margin of 24.5%, and an operating margin of 15.7%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Specialized Medical generate?
Specialized Medical reported revenue of SAR 1.5B for fiscal year 2025, with net income of SAR 266M and earnings per share (EPS) of 1.06. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Specialized Medical pay a dividend?
Specialized Medical offers a trailing dividend yield of about 7.2%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Specialized Medical financially healthy?
Specialized Medical carries a debt-to-equity ratio of 0.81x and a current ratio of 1.10x, with a market beta of 0.78. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Specialized Medical a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Specialized Medical (4019) the key facts are: market cap SAR 3.9B, P/E 14.3x, revenue SAR 1.5B, 52-week range 15.44-21.53. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Specialized Medical's full fundamentals live
Get Specialized Medical's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.